Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes

Current HIV Research

Volumn 6, Issue 3, 2008, Pages 218-229

  Matoba, Nobuyiki ^a   Griffin, Tagan A ^a   Mittman, Michele ^a   Doran, Jeffrey D ^a   Alfsen, Annette ^b   Montefiori, David C ^c   Hanson, Carl V ^d   Bornsel, Morgane ^d   Mor, Tsafrir S ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b INSTITUT COCHIN   (France)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

Author keywords

Functional non neutralizing antibodies; HIV vaccine; Mucosal transmission; Prime boost; Transcytosis

Indexed keywords

CD4 ANTIGEN; CHOLERA TOXIN B SUBUNIT; EPITOPE; GANGLIOSIDE GM1; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10;

AFFINITY CHROMATOGRAPHY; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ANTIVIRAL ACTIVITY; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PROTEIN DOMAIN; PROTEIN PURIFICATION; REVIEW; TRANSCYTOSIS; VACCINATION; VACCINE PRODUCTION; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BINDING, COMPETITIVE; CHOLERA TOXIN; EPITOPES; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; HT29 CELLS; HUMANS; IMMUNIZATION; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RABBITS; RECOMBINANT FUSION PROTEINS;

EID: 47749107594     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208784324994     Document Type: Review

References (56)

1. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004; 4:199-210.
2. Zwick MB, Labrijn AF, Wang M, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001; 75:10892-10905.
3. Parker CE, Deterding LJ, Hager-Braun C, et al. Fine definition of the epitope on the gp41 glycopirotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol 2001; 75:10906-10911.
4. Muster T, Steindl F, Purtscher M, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67:6642-6647.
5. Brunel FM, Zwick MB, Cardoso RK et al. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J Virol 2006; 80:1680-1687.
6. Zwick MB. The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring. AIDS 2005; 19:1725-1737.
7. Alfsen A, Bomsel M. HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J Biol Chem 2002; 8: 8.
8. Alfsen A, Yu H, Magerus-Chatinet A, Schmitt A, Bomsel M. HIV-1-infected blood mononuclear cells form an integrin- and agrin-dependent viral synapse to induce efficient HIV-1 transcytosis across epithelial cell monolayer. Mol Biol Cell 2005; 16(9): 4267-79.
9. Devito C, Hinkula J, Kaul R, et al. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr 2002; 30: 413-420.
10. Devito C, Broliden K, Kaul R, et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000; 165:5170-5176.
11. Devito C, Hinkula J, Kaul R, et al. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralin a primary HIV-1 isolate. AIDS 2000; 14:1917-1920.
12. Broliden Y, Hinkula J, Devito C, et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett 2001; 79: 29-36.
13. Kaul R, Plummer F, Clerici M, Bomsel M, Lopaloo L, Broliden K. Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS 2001; 15: 431-432.
14. Belec L, Ghys PD, Hocini H, et al. Cervicovaginal secretory anti-bodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J Infect Dis 2001; 184: 1412-1422.
15. Matoba N, Geyer BC, Kilbourne J, Alfsen A, Bomsel M, Mor TS. Humoral immune responses by prime-boost heterologous route immunizations with CrB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate. Vaccine 2006; 24: 5047-5055.
16. Matoba N, Magerus A, Geyer BC, et al. A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. Proc Natl Acad Sci USA 2004; 101: 13584-13589.
17. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1992; 157: 105-132.
18. Hopp TP, Woods KR. Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci USA 1981; 78:3824-3828.
19. Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10108-10125.
20. D'Souza MP, Milman G, Bradac JA, McPhee D, Hanson CV, Hendry RM. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS 1995; 9: 867-874.
21. Wang CY, Sawyer LS, Murthy W et al. Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. Proc Natl Acad Sci USA 1999; 96: 10367-10372.
22. Wang CY, Shen M, Tam G, et al. Synthetic AIDS vaccine by targeting HIV receptor. Vaccine 2002; 21: 89-97.
23. Bomsel M, Heyman M, Hocini H, et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIg;A or IgM. Immunity 1998; 9:277-287.
24. Choi JH, Lee SY. Secretory and extracellular production of recombinant proteins using Escherichia coli. Appl Microbiol Biotechnol 2004; 64: 625-635.
25. Yasuda Y, Matano K, Asai T, Tochikubo K. Affinity purification of recombinant cholera toxin B subunit oligomer expressed in Bacillus brevis for potential human use as a mucosal adjuvant. FEMS Immunol Med Microbiol 1998; 20: 311-318.
26. Uesaka Y, Otsuka Y, Lin Z, et al. Simple method of purification of Escherichia coli heat-labile enterotaxin and cholera toxin using immobilized galactose. Microb Pathog 1994; 16: 71-76.
27. Gray ES, Meyers T, Gray G, Montefiori DC, Morris L. Insensitivity of Paediatric HIV-1 Subtype C Viruses to Broadly Neutralising Monoclonal Antibodies Raised against Subtype B. PLoS Med 2006; 3: e255.
28. Li B, Decker JM, Johnson RW, et al. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 2006; 80: 5211-5218.
29. Binley JM, Wrin T, Korber B, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78:13232-13252.
30. Zwick MB, Jensen R, Church S, et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 2005; 79:1252-1261.
31. Lenz O, Dittmar MT, Wagner A, et al. Trimeric membrane-anchored gp41 inhibits HIV membrane fusion. J Biol Chem 2005; 280: 4095-4101.
32. Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995; 2: 1075-1082.
33. Mantis NJ, Kozlowski PA, Mielcarz DW, Weissenhom W, Neutra MR. Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies. Vaccine 2001; 19: 3990-4001.
34. Qiao ZS, Kim M, Reinhold B, Montefiori D, Wang JH, Reinherz EL. Design, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration. J Biol Chem 2005; 280: 23138-23146.
35. Schibli DJ, Montelaro RC, Vogel HJ. The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles. Biochemistry (Mosc) 2001; 40: 9570-9578.
36. Tan K, Liu J, Wang J, Shen S, Lu M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci USA 1997; 94: 12303-12308.
37. Trivedi VD, Cheng SF, Wu CW, Karthikeyan R, Chen CJ, Chang DK. The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20. Protein Eng 2003; 16:311-317.
38. Viard M, Blumenthal R, Raviv Y. Improved separation of integral membrane proteins by continuous elution electrophoresis with simultaneous detergent exchange: application to the purification of the fusion protein of the human immunodeficiency virus type 1. Electrophoresis 2002, 23:1659-1666.
39. Weissenhom W, Calder LJ, Dessen A, Laue T, Skehel JJ, Wiley DC. Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV- 1 gp41 ectodomain expressed in Escherichia coli. Proc Natl Acad Sci USA 1997; 94:6065-6069.
40. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997; 387: 426-430.
41. Weissenhorn W, Wharton SA, Calder LJ, et al. The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha- helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO J 1996; 15: 1507-1514.
42. Wingfield PT, Stahl SJ, Kaufman J, et al. The extracellular domain of immunodeficiency virus gp41 protein: expression in Escherichia coli, purification, and crystallization. Protein Sci 1997; 6: 1653-1660.
43. Santona A, Carta F, Fraghi P, Turrini F. Mapping antigenic sites of an immunodominant surface lipoprotein of Mycoplasma agalactiae, AvgC, with the use of synthetic peptides. Infect Immun 2002; 70: 171-176.
44. Vanniasinkam T, Barton MD, Heuzenroeder MW. B-Cell epitope mapping of the VapA protein of Rhodococcus equi: implications for early detection of R. equi disease in foals. J Clin Microbiol 2001; 39:1633-1637.
45. Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PT. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol 2003; 170: 4242-4253.
46. Saez-Cirion A, Arrondo JL, Gomara MJ, et al. Structural and functional roles of HIV-1 gp41 pretransmembrane sequence segmentation. Biophys J 2003; 85:3769-3780.
47. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, Harrison SC. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005; 433: 834-841.
48. Liljeqvist S, Ståhl S, Andréoni C, Binz H, Uhlén M, Murby M. Fusions to the cholera toxin B subunit: influence on pentamerization and GM1 binding. J Immunol Methods 1997; 210: 125-135.
49. George-Chandy A, Eriksson & Lebens M, Nordstrom I, Schon E, Holmgren J. Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells. Infect Immun 2001; 69: 5716-5725.
50. Bienenstock J, McDermott MR. Bronchus- and nasal-associated lymphoid tissues. Immunol Rev 2005; 206: 22-31.
51. Alfsen A, Iniguez P, Bouguyon E, Bomsel M. Secretory IgA Specific for a Conserved Epitope on gp41 Envelope Glycoprotein Inhibits Epithelial Transcytosis of HIV-1. J Immunol 2001; 166: 6257-6265.
52. Robinson WE Jr, Gorny MK, Xu JY, Mitchell WM, Zolla-Pazner S. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol 1991; 65: 4169-4176.
53. Finnegan CM, Berg W, Lewis GK, DeVico AL. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion. J Virol 2002; 76: 12123-12134.
54. Binley JM, Ditzel HJ, Barbas CF 3rd, et al. Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. ADS Res Hum Retroviruses 1996; 12: 911-924.
55. Tyler DS, Stanley SD, Zolla-Pazner S, et al. Identification of sites within gp41 that serve as targets for ahibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol 1990; 145: 3276-3282.
56. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-104.